Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CST-2032
- Development stage
- Phase 3
- Lead developer
- CuraSen Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CST-2032 is a proprietary, oral, brain-penetrant small molecule that acts as a beta-2 adrenoceptor (β2-adrenergic receptor) agonist. It is being developed by CuraSen Therapeutics for the treatment of neurodegenerative diseases, specifically mild cognitive impairment and mild dementia due to Alzheimer’s disease or Parkinson’s disease. The drug works by activating norepinephrine receptors in cortical and limbic brain regions to compensate for the loss of this neurotransmitter, which occurs early in these diseases. To minimize peripheral side effects associated with β2-adrenoceptor agonists, CST-2032 is administered in combination with CST-107 (nadolol), a brain-sparing beta blocker[1][4][5]. Clinical studies have shown that this approach can improve cognition and mood in affected patients[1][4].
- Other names
- CST-2032CST2032CST 2032C2407C-2407C 2407
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on CST-2032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CST-2032.